Regenxbio Inc (RGNX)
15.78
-0.33
(-2.05%)
USD |
NASDAQ |
Apr 19, 11:40
Regenxbio Revenue (Quarterly): 22.21M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 22.21M |
| September 30, 2023 | 28.91M |
| June 30, 2023 | 19.98M |
| March 31, 2023 | 19.14M |
| December 31, 2022 | 31.34M |
| September 30, 2022 | 26.51M |
| June 30, 2022 | 32.65M |
| March 31, 2022 | 22.22M |
| December 31, 2021 | 398.66M |
| September 30, 2021 | 30.77M |
| June 30, 2021 | 22.04M |
| March 31, 2021 | 18.88M |
| December 31, 2020 | 21.44M |
| September 30, 2020 | 98.91M |
| June 30, 2020 | 16.57M |
| March 31, 2020 | 17.64M |
| December 31, 2019 | 11.77M |
| September 30, 2019 | 14.70M |
| June 30, 2019 | 7.881M |
| Date | Value |
|---|---|
| March 31, 2019 | 0.884M |
| December 31, 2018 | 40.78M |
| September 30, 2018 | 5.306M |
| June 30, 2018 | 40.03M |
| March 31, 2018 | 132.39M |
| December 31, 2017 | 2.04M |
| September 30, 2017 | 1.336M |
| June 30, 2017 | 6.562M |
| March 31, 2017 | 0.455M |
| December 31, 2016 | 1.696M |
| September 30, 2016 | 0.125M |
| June 30, 2016 | 2.375M |
| March 31, 2016 | 0.393M |
| December 31, 2015 | 4.448M |
| September 30, 2015 | 1.14M |
| June 30, 2015 | 1.363M |
| March 31, 2015 | 0.644M |
| December 31, 2014 | 1.148M |
| September 30, 2014 | 0.483M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
7.881M
Minimum
Jun 2019
398.66M
Maximum
Dec 2021
45.38M
Average
22.04M
Median
Jun 2021
Revenue (Quarterly) Benchmarks
| Sarepta Therapeutics Inc | 396.78M |
| Amgen Inc | 8.196B |
| Gilead Sciences Inc | 7.114B |
| AbbVie Inc | 14.30B |
| Bristol-Myers Squibb Co | 11.48B |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -62.89M |
| Total Expenses (Quarterly) | 86.12M |
| EPS Diluted (Quarterly) | -1.42 |
| Enterprise Value | 514.02M |
| Gross Profit Margin (Quarterly) | 49.41% |
| Profit Margin (Quarterly) | -283.1% |
| Earnings Yield | -38.15% |
| Normalized Earnings Yield | -39.79 |